| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 01/27/2004 | US6682758 Water-insoluble drug delivery system |
| 01/27/2004 | US6682757 Patch units |
| 01/27/2004 | US6682756 Flexible; break and tear resistant; storage stable |
| 01/27/2004 | US6682750 Surfactant-free cosmetic, dermatological and pharmaceutical compositions |
| 01/27/2004 | US6682747 Process for preparing an oral suspension of a pharmaceutical substance |
| 01/27/2004 | US6682734 Anti-cd20 derived from transfectoma having atcc deposit numbers 69119 and hbe 1388 respectively; depletion of peripheral blood b cells |
| 01/27/2004 | US6682727 Site specific ligation of proteins to synthetic particles |
| 01/27/2004 | US6682348 Dispensing apparatus and cartridge |
| 01/27/2004 | CA2179682C Pharmaceutical, orally applicable composition |
| 01/27/2004 | CA2144094C Pharmaceutical preparation controlled to release medicinal active ingredient at targeted site in intestinal tract |
| 01/27/2004 | CA2123739C Formulations containing carotenoids and procarotenoids combined with polyphenols in the prevention of the damages due to an abnormal production of free radicals |
| 01/27/2004 | CA2120048C Pharmaceutical composition having analgesic activity |
| 01/27/2004 | CA2109150C Heat sealable shrink laminate |
| 01/27/2004 | CA2105374C Method of producing sustained-release microcapsules |
| 01/27/2004 | CA2092979C Cyclodextrin inclusion complex of paclitaxel, and method for its production and its use |
| 01/22/2004 | WO2004008101A2 The use of isocyanate linkers to make hydrolyzable active agent biopolymer conjugates |
| 01/22/2004 | WO2004007721A1 Conjugate for double-stranded rna sequence releasing and methods thereof |
| 01/22/2004 | WO2004007593A1 Poly-gamma-glutamate having ultra high molecular weight and method for using the same |
| 01/22/2004 | WO2004007588A1 Biodegradable phase separated segmented multi block co-polymers |
| 01/22/2004 | WO2004007557A2 Tf antagonist |
| 01/22/2004 | WO2004007520A2 Methods and compositions for preventing oxidative degradation of proteins |
| 01/22/2004 | WO2004006966A1 Steroid conjugates, preparation thereof and the use thereof |
| 01/22/2004 | WO2004006964A1 Microbubble compositions, and methods for preparing and using same |
| 01/22/2004 | WO2004006962A2 A tissue factor binding immunoconjugate comprising factor viia |
| 01/22/2004 | WO2004006961A1 Composition for cytocompatible, injectable, self-gelling chitosan solutions for encapsulating and delivering live cells or biologically active factors |
| 01/22/2004 | WO2004006960A1 Transdermal absorption preparation |
| 01/22/2004 | WO2004006959A1 Liquid dosage compositions of stable nanoparticulate active agents |
| 01/22/2004 | WO2004006958A1 Stable pharmaceutical composition comprising erythropoietin |
| 01/22/2004 | WO2004006957A1 Pharmaceutical compositions for otic use |
| 01/22/2004 | WO2004006954A2 Transdermal botulinum toxin compositions |
| 01/22/2004 | WO2004006948A1 Stable pharmaceutical composition comprising erythropoietin |
| 01/22/2004 | WO2004006945A1 Tablet composition containing chinese orthodox medicine extract and process for producing the same |
| 01/22/2004 | WO2004006942A1 Method for sustaining direct cell delivery |
| 01/22/2004 | WO2004006929A1 Composition for nasal absorption |
| 01/22/2004 | WO2004006905A1 Modafinil pharmaceutical compositions |
| 01/22/2004 | WO2004006897A1 Aqueous dispersions of nanometric or micrometric particles for encapsulating chemical compounds |
| 01/22/2004 | WO2004006895A1 Lasofoxifene tablet and its coating |
| 01/22/2004 | WO2004006890A1 Non-polymeric lipophilic pharmaceutical implant compositions for intraocular use |
| 01/22/2004 | WO2004006889A1 Bioerodible film for ophthalmic drug delivery |
| 01/22/2004 | WO2004006886A2 Injectable depot formulation comprising crystals of iloperidone |
| 01/22/2004 | WO2004006885A2 Systems for releasing active ingredients, based on biodegradable or biocompatible polymers with a shape memory effect |
| 01/22/2004 | WO2004006860A2 Compositions and uses thereof for identifying and targeting provasopressin-expressing cancer cells |
| 01/22/2004 | WO2004006801A2 Treatment for dry eye syndrome |
| 01/22/2004 | WO2004006756A2 THERAPIES FOR RENAL FAILURE USING INTERFERON-β |
| 01/22/2004 | WO2004006692A1 Improved bulking agent compositions |
| 01/22/2004 | WO2003097107A3 Controllably degradable polymeric biomolecule or drug carrier and method of synthesizing said carrier |
| 01/22/2004 | WO2003092649A3 Reduced formate poly(alkylene oxides) with secondary amines for reducing impurity formation |
| 01/22/2004 | WO2003092590A3 Formulations containing amiodarone and sulfoalkyl ether cyclodextrin |
| 01/22/2004 | WO2003082213A3 Compositions and methods for delivering pharmaceutically active agents using nanoparticulates |
| 01/22/2004 | WO2003074569A3 Bispecific antibody point mutations for enhancing rate of clearance |
| 01/22/2004 | WO2003072022A3 Oral trimethobenzamide formulations and methods |
| 01/22/2004 | WO2003068161A3 Composition and method for protecting labile active components |
| 01/22/2004 | WO2003066022A3 Stable pharmaceutical composition useful for treating gastrointestinal disorders |
| 01/22/2004 | WO2003061402A3 Reduction of renal damage in companion animals |
| 01/22/2004 | WO2003059286A3 Methods and compositions for oxygen transport comprising modified hemoglobin in plasma |
| 01/22/2004 | WO2003051979A3 Compositions and methods for high sorption of skin materials and delivery of sulfur |
| 01/22/2004 | WO2003045431A3 Methods for treating cancer using a combination of a tumor-derived dendritic cell inhibitory factor antagonist and a toll-like receptor agonist |
| 01/22/2004 | WO2003045326A3 Method for preparing and using polyoxyethylated castor oil in pharmaceutical compositions |
| 01/22/2004 | WO2003041637A3 Lyophilized monoclonal antibody compositions |
| 01/22/2004 | WO2003037244A3 System for manufacturing controlled release dosage forms, such as a zero-order release profile dosage form manufactured by three-dimensional printing |
| 01/22/2004 | WO2003026570A3 Reduced toxicity cisplatin formulations and methods for using the same |
| 01/22/2004 | WO2003024421A3 Triclosan dosage form |
| 01/22/2004 | WO2002065986A3 Transporters comprising spaced arginine moieties |
| 01/22/2004 | US20040016013 Achieves widespread distribution, systemic expression and sustained delivery in the animal; oral gene therapy |
| 01/22/2004 | US20040015214 Photodynamic therapy for the treatment of hair loss |
| 01/22/2004 | US20040014980 Process and intermediates |
| 01/22/2004 | US20040014961 Soluble highly branched glucose polymers and their method of production |
| 01/22/2004 | US20040014819 Otic compositions are disclosed. The compositions contain an otic drug and a carrier comprising a low molecular weight compound. The compositions do not drain out of the ear after administration. |
| 01/22/2004 | US20040014781 Compounds with sulphonamide group and pharmaceutical compositions containing these compounds |
| 01/22/2004 | US20040014750 Therapy, prevention atherosclerosis; cardiovascular disorders; anticholesterol agents; bactericides; prevention infections |
| 01/22/2004 | US20040014749 Sulfhydryl rifamycins and uses thereof |
| 01/22/2004 | US20040014718 Clear aqueous anaesthetic composition |
| 01/22/2004 | US20040014716 Composition for soluble films with a new hydrolyzed polysaccharide |
| 01/22/2004 | US20040014714 Method for producing a crystalline tableting additive, additive thus obtained and use thereof |
| 01/22/2004 | US20040014709 Genetic engineered adenoviral vector coding interferon gene; therapy against bladder cancer |
| 01/22/2004 | US20040014708 Composition comprising immunogenic microparticles |
| 01/22/2004 | US20040014704 Reducing immunology response; sustained release |
| 01/22/2004 | US20040014698 Oral administration of therapeutic agent coupled to transporting agent |
| 01/22/2004 | US20040014695 Mixture of cytolysis drug and cyclodextrin; side effect reduction; reducing ulcers |
| 01/22/2004 | US20040014693 Use of arginine in the preparation of a medicament for the prevention and treatment of the side effects associated with the intravenous administration of pharmaceuticals |
| 01/22/2004 | US20040014672 Novel crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene hydrochloride |
| 01/22/2004 | US20040014660 Insulin-associated peptides with effects on cerebral health |
| 01/22/2004 | US20040014655 Pharmaceutical compositions containing plasma protein |
| 01/22/2004 | US20040014652 Tumor activated prodrug compounds and methods of making and using the same |
| 01/22/2004 | US20040014590 Modulation pressure; efficient solvent extraction |
| 01/22/2004 | US20040014187 Comprises genetically engineered protease for treatment tumors; gene therapy |
| 01/22/2004 | US20040014164 Dried composition comprised of glassy matrix for improving stability and storage of proteins |
| 01/22/2004 | US20040014158 Protein conjugates, methods, vectors, proteins and DNA for producing them, their use, and medicaments and vaccines containing a certain quantity of said protein conjugates |
| 01/22/2004 | US20040013747 An anaesthetic mixture comprising a drug, acids, a metal nitrite; a membrane is used to prevent direct contact of the skin while diffusing the active drug and nitric oxide vasodilator; topical application |
| 01/22/2004 | US20040013746 Antidepressants for treating manic disorders, psychosis, comprising ethyl cellulose, talc, polyvinylpyrrolidone |
| 01/22/2004 | US20040013744 Antibiotic ointment for treating skin rash; simple and inexpensive |
| 01/22/2004 | US20040013740 Antitumor agents for treating tumor of mucosa, skin; poisons are selected from scolopenders, snakes, spiders or scorpions |
| 01/22/2004 | US20040013734 Mixture of water insoluble drug and polymer |
| 01/22/2004 | US20040013733 Preparation of a biodegradable thermal-sensitive gel system |
| 01/22/2004 | US20040013731 Drug-complex microparticles and methods of making/using same |
| 01/22/2004 | US20040013729 Mydriatic agent in viscoelasticity polymer |
| 01/22/2004 | US20040013728 Controlled drug delivery system using the conjugation of drug to biodegradable polyester |
| 01/22/2004 | US20040013727 Hydrophilic gel foaming matrix; cellulose ethers |
| 01/22/2004 | US20040013726 Granulation, crosslinking, drying to powder |
| 01/22/2004 | US20040013725 Storage stable thyroxine active drug formulations and methods for their production |